{"id":"W4415535704","doi":"10.1016/j.jtct.2025.10.024","title":"CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Takeda Oncology; U.S. Public Health Service; Health Resources and Services Administration; National Institutes of Health; Jazz Pharmaceuticals; Medac; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Incyte; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Gateway for Cancer Research; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Clinical trial; Cytokine release syndrome; Safety monitoring; Food and drug administration; Data monitoring committee; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01361576,0.0003405405,0.001015274,0.000550919,0.0003042003,0.001504033,0.0004389636,0.0004877327,0.002108928],"category_scores_gemma":[0.01989482,0.0001807671,0.001508691,0.001117197,0.0006399491,0.0009846105,0.0006246908,0.001000921,0.0003033139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005358071,"about_ca_system_score_gemma":0.0007903689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002911179,"about_ca_topic_score_gemma":0.001174744,"domain_scores_codex":[0.9885718,0.00610664,0.002490269,0.0008969654,0.001590066,0.0003442257],"domain_scores_gemma":[0.9539548,0.01681387,0.02421471,0.002295127,0.002026573,0.0006949191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06384961,0.001015668,0.6531903,0.007927014,0.01378802,0.001171648,0.000568893,0.002306678,0.007208837,0.001672686,0.006086773,0.2412138],"study_design_scores_gemma":[0.01004669,0.02649358,0.8936061,0.001852674,0.007324833,0.007321784,0.0007291977,0.002343952,0.008288396,0.002134798,0.03975751,0.000100601],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9191419,0.0615459,0.003769425,0.0007284762,0.0001340481,0.0008690097,0.004312411,0.00009824568,0.009400725],"genre_scores_gemma":[0.9912817,0.004276382,0.0009573504,0.0004928561,0.00009813814,0.0003408511,0.00206299,0.00001556413,0.0004741776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01361576,"threshold_uncertainty_score":0.07200789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1245555539661076,"score_gpt":0.4200015351121382,"score_spread":0.2954459811460307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}